Search

Introduction: Bone-anchored hearing aids are currently well-established solutions for treatment of hearing-impaired patients. Objective: To evaluate the surgery of the Baha® Attract system, healing process and soft tissue condition after the processor activation. Methods: 125 patients implanted with the Baha® Attract system during a 3 year period in a single ENT department were analysed. Evaluated parameters comprised: details of surgery, healing process and soft tissue condition at the time of the processor activation and on subsequent follow-up visits. Results: The implantation was conducted under local anaesthesia in 96% of patients. The mean surgery time was 42 min. Soft tissue reduction was performed in 43.2% of cases; bone polishing in 23.2% and bipolar coagulation in all the cases. Healing was uneventful in 92.8%. 10 days after the surgery, pain was reported in 48% of cases. On subsequent follow-up visits, 1 month and 3 months after the surgery, pain was present in 18.4% and 2.4% of cases respectively. Similarly, numbness and paresthesia, initially reported in 84% and 15.2%, were present in 60% and 11.2% after a month, and in 17.6% and 1.6% after three months. After the processor attachment, no serious problems were observed in the analysed group during follow-up visits. However, mild redness and/or mild pain over the magnet were observed in 9.6% of patients. Conclusion: Implantation of the Baha® Attract system is an easy and safe procedure. It can be performed under local anaesthesia in adults. There are no major surgical problems or complications, and the healing process proceeds efficiently in most patients. Postoperative pain is usually mild and gradually decreases in the following months. Numbness in the operated area is frequent, but as reinnervation occurs in time, the numb patch decreases in size and finally completely disappears in most cases. Resumo: Introdução: Os processadores de implantes auditivos de ancoragem óssea são atualmente soluções bem estabelecidas para o tratamento de pacientes com deficiência auditiva. Objetivo: Avaliar a cirurgia de implante do sistema Baha® Attract, o processo de cicatrização e a condição dos tecidos moles após a ativação do processador. Método: Foram analisados 125 pacientes implantados com o sistema Baha® Attract durante um período de 3 anos em um único departamento de otorrinolaringologia. Os parâmetros avaliados compreenderam: detalhes da cirurgia, processo de cicatrização e condição dos tecidos moles no momento da ativação do processador e nas consultas de seguimento subsequentes. Resultados: O implante foi realizado sob anestesia local em 96% dos pacientes. O tempo médio de cirurgia foi de 42 minutos. A redução de tecido mole foi realizada em 43,2% dos casos; polimento ósseo em 23,2% e coagulação bipolar em todos os casos. A cicatrização transcorreu sem complicações em 92,8%. Dez dias após a cirurgia, dor foi relatada em 48% dos casos. Nas consultas de seguimento subsequentes, 1 mês e 3 meses após a cirurgia, a dor esteve presente em 18,4% e 2,4% dos casos, respectivamente. Da mesma forma, dormência e parestesia, inicialmente relatados em 84% e 15,2%, estavam presentes em 60% e 11,2% dos casos após um mês, e em 17,6% e 1,6% após três meses. Após a fixação do processador, nenhum problema grave foi observado no grupo analisado durante as consultas de seguimento. No entanto, vermelhidão leve e/ou dor leve sobre o ímã foram observados em 9,6% dos pacientes. Conclusão: O implante do sistema Baha® Attract é um procedimento fácil e seguro. Ele pode ser realizado sob anestesia local em adultos. Não há grandes problemas ou complicações cirúrgicas, e o processo de cicatrização é contínuo e eficaz na maioria dos pacientes. No pós-operatório, a dor é geralmente leve e diminui gradualmente nos meses seguintes. A dormência na área operada é freqüente, mas como a reinervação ocorre com o tempo, a área dormente diminui de tamanho e finalmente desaparece por completo na maioria dos casos. Keywords: Bone conduction, Hearing aids, Hearing loss, Palavras-chave: Condução óssea, Aparelhos auditivos, Perda auditiva

Larynx squamous cell carcinoma (LSCC) is characterized by complex genotypes, with numerous abnormalities in various genes. Despite the progress in diagnosis and treatment of this disease, 5-year survival rates remain unsatisfactory. Therefore, the extended studies are conducted, with the aim to find genes, potentially implicated in this cancer. In this study, we focus on the FAM107A (3p14.3) gene, since we found its significantly reduced expression in LSCC by microarray profiling (Affymetrix U133 Plus 2.0 array). By RT-PCR we have confirmed complete FAM107A downregulation in laryngeal cancer cell lines (15/15) and primary tumors (21/21) and this finding was further supported by FAM107A protein immunohistochemistry (15/15). We further demonstrate that a combined two hit mechanism including loss of 3p and hypermethylation of FAM107A promoter region (in 9/15 cell lines (p p FAM107A expression (5 to 6 fold increase) in the UT-SCC-29 cell line, characterized by high DNA methylation. Therefore, we report the recurrent inactivation of FAM107A in LSCC, what may suggest that the gene is a promising tumor suppressor candidate involved in LSCC development.

Bone-anchored hearing aids are currently well-established solutions for treatment of hearing-impaired patients.To evaluate the surgery of the Baha125 patients implanted with the BahaThe implantation was conducted under local anaesthesia in 96% of patients. The mean surgery time was 42min. Soft tissue reduction was performed in 43.2% of cases; bone polishing in 23.2% and bipolar coagulation in all the cases. Healing was uneventful in 92.8%. 10 days after the surgery, pain was reported in 48% of cases. On subsequent follow-up visits, 1 month and 3 months after the surgery, pain was present in 18.4% and 2.4% of cases respectively. Similarly, numbness and paresthesia, initially reported in 84% and 15.2%, were present in 60% and 11.2% after a month, and in 17.6% and 1.6% after three months. After the processor attachment, no serious problems were observed in the analysed group during follow-up visits. However, mild redness and/or mild pain over the magnet were observed in 9.6% of patients.Implantation of the Baha

Protocadherins are cell-cell adhesion molecules encoded by a large family of genes. Recent reports demonstrate recurrent silencing of protocadherin genes in tumors and provide strong arguments for their tumor supresor functionality. Loss of protocadherins may contribute to cancer development not only by altering cell-cell adhesion, that is a hallmark of cancer, but also by enhancing proliferation and epithelial mesenchymal transition of cells via deregulation of the WNT signaling pathway. In this study we have further corroborated our previous findings on the involvement of PCDH17 in laryngeal squamous cell carcinoma (LSCC). We used bisulfite pyrosequencing to analyze a cohort of primary LSCC tumors for alterations in PCDH17 promoter DNA methylation as an alternative gene inactivation mechanism to the homozygous deletions reported earlier. Moreover, we analyzed primary LSCC samples by immunohistochemistry for PCDH17 protein loss. We identified recurrent elevation of PCDH17 promoter DNA methylation in 32/81 (40%) primary tumors (P